Background: Pain is processed and experienced differently on the left (L) and right (R) sides of the body; however, L/R pain asymmetry with cosmetic treatments of the face has not been evaluated.
and/or STF often remark that treatment was more painful on 1 side than on the other. Discussing this phenomenon with the patient often involves speculative explanations and theories that are not evidence-based. However, investigators have determined that patients perceive exposure of their hands to pressure or extreme temperatures as being significantly more painful in the left (L) hand than the right (R). [3] [4] [5] Results of neuroimaging studies indicate that pain processing is predominantly localized in the R hemisphere in specific regions of the cortex, and the existence of an R-lateralized attentional system to alert organisms to pain has been proposed. [6] [7] [8] [9] Moreover, processing of negative emotions, symptoms of depression, and pain correlates significantly with increased activity of the R frontal lobe. [10] [11] [12] [13] [14] Various closely linked biological and psychological mechanisms affect the experience of pain. The relationships among these mechanisms have been described by Melzack and Wall. 15 In 1965, these authors proposed the gate control theory of pain, which states that a non-noxious stimulus can suppress pain. 15 Other investigators have applied and extended the gate control theory to understand the power of mental distraction and to utilize competing stimuli to lessen pain perception (ie, conditioned pain modulation). 16 Herein, we describe our findings of pain intensity perceptions on the L and R sides of the face for patients who underwent BTX and/or STF treatment.
METHODS
Patients who underwent aesthetic facial treatments with BTX and/or STF (ie, calcium hydroxyapatite and/or hyaluronic acid) at 5 aesthetic medicine training institutes in the Netherlands, from May 2015 to August 2015, were evaluated in a cross-sectional multicenter pragmatic study. The study was not blinded, and a control group was not included. All patients were ≥18 years of age. Exclusion criteria were neurological disorders or objective differences on the R and L sides of the face regarding response to touch, pain, pressure, or temperature. This study was approved by the Medical Ethical Committee of the Academic Medical Center of the University of Amsterdam (Netherlands) and was conducted in accordance with guidelines set forth in the Declaration of Helsinki.
At the first pretreatment visit, the study was described to patients by reception staff, and patients provided informed consent and completed an initial questionnaire (Appendix A, available as Supplementary Material at www.aestheticsurgeryjournal.com). Tactile asymmetry of the face was determined objectively by applying a cotton swab while the patient's eyes were closed. Patients also were asked whether they regarded themselves as having asymmetric facial sensitivity.
The side of the face to receive the first injection was predetermined randomly. Specifically, medical forms were numbered consecutively as patients agreed to participate in the study. Patients whose form had an uneven number received the first injection on the L side of the face, and those with even-numbered forms received the first injection on the R side.
Each patient received BTX and/or STF treatment from 1 physician. Physicians with experience performing injectable cosmetic treatments for the face were present at all 5 participating institutes. (Clinic 28 included 1 physician with 4 years of experience; Clinique Dr Don included 2 physicians with 1 and 16 years of experience; DermaClinic included 3 physicians with 1, 2, and 13 years of experience; Doctors Inc. included 3 physicians with 1, 2, and 12 years of experience; and Kliniek aan de Maas included 2 physicians with 2 and 23 years of experience.)
Within 5 minutes after treatment, patients were asked to rate the degree of pain on each side of the face on a visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst pain) at 0.5-unit intervals. Responses were recorded on a form that lacked identifying information other than the study number (Appendix B, available as Supplementary Material at www.aestheticsurgeryjournal. com). VAS scores were analyzed with Microsoft Excel for Mac 2011 software (version 14.6.2; Redmond, WA). Distributions were determined for baseline characteristics, and data for the 2 sides of the face were compared with paired 2-tailed t tests. Subgroup analyses were performed to evaluate patient-specific information (eg, handedness, gender), treatment characteristics (eg, needle size), and overall pain perceptions for BTX vs STF. Statistical significance was defined as P < 0.05.
RESULTS
A total of 315 patients agreed to participate in the study. Some data were incomplete for 19 patients; 13 of these patients were excluded from the study because the treatment or study protocol was not followed correctly (n = 4) or because key data (eg, VAS scores) were missing (n = 9). The remaining 302 patients (283 [94%] women) were included in the analyses. In total, 349 treatments were performed (244 BTX, 105 STF). The patients' mean age was 43 years (standard deviation [SD], 11 years; range, 21-76 years), and 33 patients (11%) were L-handed. Baseline characteristics of patients and treatments performed are summarized in Table 1 . All physicians who administered study treatments were R-handed, and there were no significant differences in the number of treatments performed by each physician. BTX treatments were delivered with needles, whereas STF treatments were delivered with needles or cannulae. The specific materials (dermal products and needle/cannula sizes) utilized at each institute are listed in Table 2 . With the exception of minor bruising, no other adverse effects were observed during or after the treatments.
Results of pain severity by treatment modality are depicted in Figure 1 and Table 3 . For BTX and STF treatments, patients reported significantly higher VAS scores (ie, more painful) for the L side of the face. When VAS scores for BTX and STF treatments were combined, these ratings remained significantly higher for the L side of the face. Moreover, STF treatments were perceived as more painful than BTX treatments. VAS scores according to patient handedness and the side of initial injection are shown in Supplemental Table 1 (available as Supplementary Material at www.aestheticsurgeryjournal.com). R-handed patients (n = 269) reported significantly higher individual and combined VAS scores for BTX and/or STF treatments than did L-handed patients (n = 33). Patients who underwent the first injection on the L side of the face (n = 151) reported significantly lower individual and combined VAS scores for BTX and/or STF treatments than did patients who received the first treatment on the R side (n = 198). The reported individual and combined VAS scores for BTX and/or STF treatments were lower for men (n = 19) than women (n = 283) ( Table 4) . Compared with the 4 other participating institutes, DermaClinic tended to have higher combined VAS scores for BTX and STF treatments and had substantially higher VAS scores for BTX alone (Table 3) . At DermaClinic, BTX treatments were administered with a 29-gauge (G) needle, whereas a 33-G needle was employed at the other institutes (Table 2 ).
DISCUSSION
We demonstrated that, during and shortly after bilateral facial treatment with BTX and/or STF, patients experienced significantly more pain on the L side. However, when the first BTX and/or STF injection was made on the L side of the face, patients rated the overall treatment as less painful than when the first injection was made on R side of the face. Moreover, STF treatments were perceived as more painful than BTX treatments, and R-handed patients experienced more pain than L-handed patients with BTX and STF treatments. For BTX treatments, a smaller needle diameter was associated with less pain (Tables 2 and 3) .
To our knowledge, this is the first study to address R/L facial pain severity with BTX and/or STF treatment. The VAS is a standard, highly efficient method to assess pain intensity. To evaluate pain level more specifically, our VAS contained intervals of 0.5 rather than 1.0 (as in the typical scale). Our observations support that specific adjustments to injection techniques may decrease pain and discomfort, and in turn, yield greater patient satisfaction.
Various studies have addressed pain asymmetry after the application of noxious stimuli to the hands and/or arms. In a study by Sarlani et al, 3 40 healthy individuals rated pain intensity when the L or R hand was immersed in hot or cold water (temperature range, 10°C and 47°C). They found that individuals perceived greater pain when the L hand was immersed. 3 Pauli et al 4 examined pain thresholds for 8 participants by means of electroencephalography for a 6-week period; pain thresholds were lower for the L hand. In a study by Lugo et al, 5 351 participants immersed both hands in a 48°C water bath for 15 seconds and reported pain severity on a VAS. Pain was significantly worse for the L hand. 5 Spernal et al 10 evaluated thresholds for pressure, cold, and heat pain on the R/L forearm or hand for healthy patients (n = 20) and for patients with major depressive disorder (n = 21) or panic disorder (n = 21). These authors found that participants had greater pain sensitivity on the L side for pressure, but no pain asymmetry for cold/heat stimuli. 10 Findings of these studies are consistent with those of our study of facial pain asymmetry and support the phenomenon that patients perceive pain as being more intense on the L side of the body. Pauli et al 17 compared pressure pain threshold (PPT) asymmetry for 12 R-handed and 12 L-handed patients and found that R-handed patients experience PPT asymmetry, with greater pain sensitivity in the L hand. This association with handedness is similar to our results, in which R-handed patients scored BTX and STF treatments as more painful than did L-handed patients. Several investigators also have demonstrated that women have lower thresholds of pain sensitivity and enhanced pain facilitation compared with men. 18, 19 This finding has been attributed to a complex array of factors, ranging from biologic (eg, hormonal, genetic) to psychologic (eg, pain coping) to sociocultural (eg, gender roles). 18, 19 Similarly, we demonstrated that BTX and STF treatments were perceived as more painful by women.
Arendt-Nielson et al 20 evaluated the effects of needle outer diameter (23 G, 27 G, 30 G, and 32 G) on pain frequency, pain intensity, and occurrence of bleeding. Consistent with our study, these authors concluded that needle size correlates positively and significantly with the frequency of pain during insertion. 20 The 5 clinics in our study had different needle/cannula preferences for STF treatments, and therefore we could not conclude whether patients experienced more pain with needles or cannulae. The safety of needles for STF treatments currently is under debate and warrants additional research, especially for regions of the face in which intravascular placement of needles could lead to severe complications.
Our study had several limitations. All physicians who performed treatments in this study were R-handed. It is possible that the approach and orientation of the physician on either side of the patient's face could differ by physician handedness. Physicians positioned themselves on the side of the patient that was undergoing treatment, rather than leaning over the patient to perform the contralateral treatment. We believe that this method ensured optimal delivery distances and physical ergonomics for both sides of the face.
Although we intended, through randomization, to have an equal number of patients receive their first injection on each side, ultimately we determined that 131 patients (43%) initially were treated on the L side and 171 patients (57%) on the R side (Supplemental Table 1 ). (Forty-two patients were incorrectly treated first on the R side, and 2 patients were incorrectly treated first on the L side.) Physician handedness likely contributed to this. Several physicians disregarded or forgot the assigned starting treatment side. In our experience, most physicians (especially R-handed physicians) naturally approach patients from the R side for examination and treatment. When these 44 patients (51 treatments) were removed from the analyses, our results were unchanged. Therefore, we do not believe that incomplete randomization compromised this study.
Our pragmatic study design obviated any neurophysiologic explanation for our findings. In addition, matching was omitted, and we did not perform sample-size calculations in advance of this study. Therefore, the statistical power for subgroup analyses of patient handedness and gender was limited. Sample sizes for all other comparisons were more than adequate. Because we did not include any control groups, blinding was not needed. We cannot rule out that the lack of blinding may have biased physicians' techniques (eg, carrying out treatments differently or delivering more treatments to 1 side of the face). However, baseline characteristics of the treatment groups did not differ significantly with respect to age, race, or asymmetry of facial sensitivity. We are confident that physicians in this study sought to minimize patient discomfort and achieve good aesthetic results and would not intentionally introduce pain asymmetry. Although we did not collect data regarding the number of injections per patient on each side of the face, patients who undergo BTX and/or STF treatments typically receive an equal number of injections on the R and L sides. Topical anesthetics or ice packs were applied for a few patients, and some patients received injections of local anesthetic (especially for STF treatment) before the site was prepared for cannula insertion. Although patients who received pain management would likely have experienced less pain, anesthetics were applied to both sides of the face, so we maintain that L/R discrepancies in pain intensity would be preserved.
STF formulations vary in rheologic properties (eg, cohesiveness, viscosity, elasticity) and, therefore, the pain intensities elicited also may differ. However, the pain experienced during and immediately after STF treatment largely is caused by needle insertion and the expansion of tissue upon delivery of the filler. After some time, an STF with a low G prime could integrate and disperse more easily into surrounding tissue, potentially decreasing pressure on tissue, and in turn, decreasing pain.
CONCLUSIONS
To lessen the pain and discomfort associated with administration of BTX and/or STF, patients should first be treated on the L side of the face, and when possible, a high-G needle should be employed.
Supplementary Material
This article contains supplementary material located online at www.aestheticsurgeryjournal.com.
Disclosures
The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.
